Live feed08:00:00·40dPRReleasevia QuantisnowBelite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1ByQuantisnow·Wall Street's wire, on your screen.BLTE· Belite Bio IncHealth Care
